1796.TWO GeneFerm Biotechnology Co Ltd
- Market cap
- TWD 1.10B
- P/E
- 63.5x
- P/B
- 1.39x
- ROE
- -1.1%
- Dividend yield
- 2.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1796.TWO undervalued?
Graham number1796.TWO trades 98.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GeneFerm Biotechnology Co Ltd fundamental analysis
No fundamental analysis for GeneFerm Biotechnology Co Ltd yet.
GeneFerm Biotechnology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder…
Full company profileGeneFerm Biotechnology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GeneFerm Biotechnology Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 350M | 357M | 328M | 368M | 522M | 634M | 794M | 521M | 677M | 644M |
| Gross Profit | 148M | 118M | 77.5M | 122M | 193M | 222M | 286M | 96.7M | 191M | 141M |
| Operating Income | 36.2M | 9.82M | -23.4M | 17.5M | 79.2M | 113M | 157M | -35.5M | 46.0M | -8.81M |
| EBITDA | 64.9M | 45.9M | 14.4M | 58.6M | 125M | 163M | 231M | 56.3M | 115M | 69.2M |
| Net Income | 28.2M | 10.3M | -27.6M | 4.53M | 57.4M | 93.5M | 125M | -22.5M | 28.9M | -8.84M |
| EPS | 1.13 | 0.37 | -0.99 | 0.16 | 1.24 | 2.19 | 2.99 | -0.54 | 0.70 | -0.21 |
| Balance Sheet | ||||||||||
| Total Assets | 509M | 557M | 1.00B | 983M | 1.32B | 1.19B | 1.18B | 1.15B | 1.28B | 1.27B |
| Total Liabilities | 194M | 141M | 46.0M | 586M | 569M | 359M | 283M | 358M | 464M | 482M |
| Shareholders' Equity | 315M | 417M | 390M | 396M | 748M | 831M | 893M | 788M | 817M | 784M |
| Cash & Short-term Investments | 67.6M | 110M | 21.7M | 348M | 540M | 101M | 120M | 122M | 280M | 282M |
| Total Debt | - | - | 551M | 512M | 465M | 219M | 152M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 61.1M | 42.1M | 14.7M | 56.4M | 112M | 122M | 190M | 8.09M | 99.3M | 83.4M |
| Capital Expenditure | 55.2M | 28.8M | 54.6M | 82.3M | 146M | 278M | 71.4M | 22.7M | 23.4M | 41.0M |
| Free Cash Flow | 5.02M | 12.8M | -39.9M | -25.9M | -33.4M | -156M | 119M | -14.6M | 75.9M | 42.4M |
| Ratios | ||||||||||
| ROE | 9.0% | 2.5% | -7.1% | 1.1% | 7.7% | 11.2% | 14.0% | -2.9% | 3.5% | -1.1% |
| ROA | 5.5% | 1.9% | -2.8% | 0.5% | 4.4% | 7.9% | 10.6% | -2.0% | 2.3% | -0.7% |
| Net Profit Margin | 8.1% | 2.9% | -8.4% | 1.2% | 11.0% | 14.7% | 15.7% | -4.3% | 4.3% | -1.4% |
| Debt to Equity | - | - | 1.41x | 1.29x | 0.62x | 0.26x | 0.17x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GeneFerm Biotechnology Co Ltd dividends
- Dividend yield
- 2.66%
- Forward dividend
- 0.70 TWD
- Payout ratio
- -
- Ex-dividend date
- Jul 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 82.9M | 2.00 | - |
| 2023 | TWD 62.2M | 1.49 | 49.9% |
| 2022 | TWD 41.5M | 0.97 | 44.4% |
| 2021 | TWD 3.39M | 0.07 | 5.9% |
| 2020 | TWD 3.39M | 0.12 | 74.8% |
| 2019 | TWD 13.9M | 0.50 | - |
| 2018 | TWD 27.4M | 0.99 | 266.0% |
| 2017 | TWD 52.4M | 2.10 | 185.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns GeneFerm Biotechnology Co Ltd
- Insiders 52.42%
- Institutions 0.00%
- Public & others 47.58%
- Shares outstanding 41.5M
- Free float 20.7M
GeneFerm Biotechnology Co Ltd company profile
- Company name
- GeneFerm Biotechnology Co Ltd
- Ticker
- 1796.TWO
- ISIN
- TW0001796001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No.3, Dali 2nd Rd., Tainan City, Taiwan, 741014
- Phone
- 886 6 510 9001
- Website
- geneferm.com
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company provides microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, and fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; and microbial fermentation toll manufacturing services. The company was founded in 1999 and is headquartered in Tainan City, Taiwan.
GeneFerm Biotechnology Co Ltd management
2- Jinde JinManager
- Qimian SuAccounting Supervisor